OncoMatch/Clinical Trials/NCT06493552
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Is NCT06493552 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments for muscle-invasive bladder carcinoma.
Treatment: SEphB4-HSA · Pembrolizumab · Gemcitabine · Cisplatin · Enfortumab vedotin — Patients with solid tumors that have high expression levels of EphrinB2 are treated with regimens that include EphrinB2 inhibitor, sEphB4-HSA. The primary objective of this study is to demonstrate additive therapeutic benefit for sEphB4-HSA. The secondary objectives are to determine whether the sEphB4-HSA containing regimen is safe and whether the oncological endpoints of importance in each cohort improve as a result of treatment with sEphB4-HSA containing regimen relative to a predefined threshold or to a control arm in the cohort where available. Treatment continues until progression of disease or unacceptable toxicities arise.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Urothelial Carcinoma
Biomarker criteria
Required: EFNB2 overexpression
Tumor must express EphrinB2 as assessed by USC Norris Core Lab.
Required: NECTIN4 non-amplified
Tumor must be Nectin4 non-amplified- testing performed during pre-screening assessment.
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Tumor tissue must be submitted for molecular profile through a commercial service such as Tempus, CARIS, Foundation One, etc. This must include a PD-L1 assay.
Performance status
ZUBROD 0–1
Prior therapy
Cannot have received: systemic therapy
Exception: no systemic therapy for cancer in the previous 12 months
No systemic therapy for cancer in the previous 12 months.
Lab requirements
Blood counts
wbc ≥2000/ul; neutrophils ≥1500/ul; platelets ≥100x103/ul; hemoglobin ≥9g/dl
Kidney function
measured or calculated creatinine clearance (crcl) greater than or equal to 30 ml/min using the cockcroft-gault formula using actual weight
Liver function
ast ≤3 x uln; alt ≤3 x uln; bilirubin ≤1.5 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sarcoma Oncology Center · Santa Monica, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06493552 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EFNB2?
Yes, EFNB2 overexpression is a required biomarker for enrollment.
Does this trial require NECTIN4?
Yes, NECTIN4 non-amplified is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages